Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.

Background: NCCN defines distress as a multifactorial, unpleasant emotional experience of a psychological nature that may interfere with patients' ability to cope with cancer symptoms and treatment. Patients with myelodysplastic syndromes (MDS) are at risk for distress due to the largely incurable nature of this hematopoietic malignancy and its symptom burden, yet associations with clinical outcomes are unknown. Methods: We retrospectively reviewed patient-reported distress data from adult ambulatory patients with MDS visiting a single, tertiary care medical center from July 2013 to September 2015. Demographic, diagnostic, treatment, and comorbidity information were abstracted from records along with NCCN Distress Thermometer (DT) and Problem List (PL) scores. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards regression. Results: We abstracted 376 DT scores (median, 1; range, 0-10) from 606 visits and 110 patients (median, 2 DT scores/patient; range, 1-16). NCCN Guidelines suggest that patients with DT scores ≥4 should be evaluated for referral to specialty services to address unmet needs. A total of 54 patients (49%) had at least 1 DT score ≥4 and 20 (18%) had 2 or more DT scores ≥4; 98 patients (89.1%) reported 1,379 problems during 23,613 person-days of follow-up (median, 4 problems/patient/visit; range, 1-23). The 5 most frequently reported problems were fatigue (181 times; 78 patients), pain (95 times; 46 patients), worry (80 times; 45 patients), sleep (78 times; 41 patients), and tingling hands/feet (68 times; 33 patients). After adjustment for risk stratification at diagnosis, a single point increase on the DT was associated with an increased risk of death (hazard ratio, 1.18; 95% CI, 1.01-1.36). Conclusions: Patients with MDS experience a high burden of distress, and patient-reported distress is associated with clinical outcomes. Distress should be further studied as a prognostic variable and a marker of unmet needs in MDS.

[1]  M. Clark,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Distress Management, Version 3.2019 , 2019 .

[2]  A. El-Jawahri,et al.  Palliative and End-of-Life Care in Myelodysplastic Syndromes , 2016, Current Hematologic Malignancy Reports.

[3]  G. Abel,et al.  Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS) , 2016, Haematologica.

[4]  T. Leblanc Addressing End-of-Life Quality Gaps in Hematologic Cancers: The Importance of Early Concurrent Palliative Care. , 2016, JAMA internal medicine.

[5]  M. Sprangers,et al.  Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. , 2015, The Lancet. Oncology.

[6]  F. Mandelli,et al.  Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes , 2015, British journal of haematology.

[7]  Lisa VanHoose,et al.  An analysis of the distress thermometer problem list and distress in patients with cancer , 2015, Supportive Care in Cancer.

[8]  J. Troy,et al.  Myelodysplastic syndromes in the United States: an update for clinicians , 2014, Annals of medicine.

[9]  A. Beekman,et al.  Distress, problems and supportive care needs of patients treated with auto- or allo-SCT , 2014, Bone Marrow Transplantation.

[10]  Hodgkin Lymphoma NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[11]  L. Traeger,et al.  Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Wallen,et al.  Distress screening in allogeneic hematopoietic stem cell (HSCT) caregivers and patients , 2011, Psycho-oncology.

[13]  C. Parry,et al.  What do 1281 distress screeners tell us about cancer patients in a community cancer center? , 2011, Psycho-oncology.

[14]  J. Sloan,et al.  Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. , 2008, Leukemia research.

[15]  K. Heptinstall Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc. , 2008, Oncology.

[16]  P. Jacobsen,et al.  Validation of the Distress Thermometer with bone marrow transplant patients , 2006, Psycho-oncology.

[17]  Zeev Rosberger,et al.  Psychological Distress and Cancer Survival: A Follow‐Up 10 Years After Diagnosis , 2003, Psychosomatic medicine.

[18]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Steven Piantadosi,et al.  The prevalence of psychological distress by cancer site , 2001, Psycho-oncology.